On March 27, 2024 GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, reported that it will present new data on the clinical utility of its Methylation Platform across the cancer continuum, and the impact of multi-cancer early detection (MCED) testing in guiding diagnostic evaluation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in San Diego, Calif., April 5-10, 2024 (Press release, Grail, MAR 27, 2024, View Source [SID1234641524]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The data we are presenting at AACR (Free AACR Whitepaper) continue to support the potential of GRAIL’s Methylation Platform to transform cancer care and the potential benefits of population-scale asymptomatic (or early) cancer detection," said Jeffrey Venstrom, MD, Chief Medical Officer at GRAIL. "Our longer-term research demonstrates that adding MCED tests like Galleri to guideline-recommended screenings can help direct diagnostic evaluation and underscores the potential value of repeat MCED screening. Additionally, new data from our Methylation Platform suggests the ability to identify relevant cancer subtypes using a single blood test, helping to enable precision medicine and biomarker discovery."

In the MCED setting, GRAIL is honored to present 3 oral presentations at AACR (Free AACR Whitepaper):

Demonstrating the first real-world evaluation of repeat MCED / Galleri testing showing the potential value of adding repeat MCED screening. The timeframe for repeat testing occurred 10-18 months from initial MCED testing.
Exhibiting 4-year overall survival follow-up demonstrating the prognostic significance of detecting cancer with a methylation-based cfDNA platform like Galleri.
Illustrating data demonstrating the power of Galleri to preferentially detect high grade, clinically significant prostate cancer over indolent cases.
In the precision oncology setting, GRAIL will discuss the adaptability of its Methylation Platform in identifying cancer histological and molecular subtypes through blood samples.

Oral Presentations

Title: Early Real-World Experience with Repeat Multi-Cancer Early Detection (MCED) Testing
Abstract Number: #3891
Session Category: Clinical Research
Session Title: Application of Real-World Evidence to Cancer Care
Date/Time: Monday, Apr. 8, 2024 from 2:30 PM – 4:30 PM
Location: Room 6 CF – Upper Level – Convention Center

Title: A Targeted Methylation-Based Multi-Cancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer and Minimizes Overdiagnosis
Abstract Number: #1264
Session Category: Prevention / Early Detection / Interception
Session Title: Multi-Cancer Early Detection Testing: Where Are We?
Date/Time: Sunday, Apr. 7, 2024 from 3:00 PM – 5:00 PM
Location: Room 28 – Upper Level – Convention Center

Title: Prognostic Significance of Blood-Based Multi-Cancer Detection in Cell-Free DNA: 4-Year Outcomes Analysis
Abstract Number: #3895
Session Category: Clinical Research
Session Title: Early Detection and Progression Biomarkers
Date/Time: Monday, Apr. 8, 2024 from 2:30 PM – 4:30 PM
Location: Ballroom 6 B – Upper Level – Convention Center

Poster Sessions

Title: PATHFINDER 2: A Prospective Study to Evaluate Safety and Performance of a Multi-Cancer Early Detection Test in a Population Setting
Abstract Number: #4784
Session Category: Prevention / Early Detection / Interception
Session Title: Population-Based Screening
Date/Time: Tuesday, Apr. 9, 2024 from 9:00 AM – 12:30 PM
Location: Poster Section 32

Title: Identification of Cancer Subtypes with a ctDNA-based Targeted Methylation Assay
Abstract Number: #7566
Session Category: Clinical Research
Session Title: Molecular Biology in Clinical Oncology: Characterizing and Modulating Epigenetics and Gene Expression
Date/Time: Wednesday, Apr. 10, 2024 from 9:00 AM – 12:30 PM
Location: Poster Section 43

Title: Most Cancer Deaths are Unaddressed by Current Screening Paradigms
Abstract Number: #6075
Session Category: Prevention / Early Detection / Interception
Session Title: Biomarker-Based Screening
Date/Time: Tuesday, Apr. 9, 2024 from 1:30 PM – 5:00 PM
Location: Poster Section 31

Title: Association of Circulating Free DNA (cfDNA) Maximum Variant Allele Frequency (mVAF) Levels with Clinical Outcomes in Patients (pts) with Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) Treated with Pembrolizumab (pembro) + Chemotherapy (chemo) in the Phase 2 KEYNOTE-782 Trial
Abstract Number: #LB107
Session Category: Clinical Research
Session Title: Late-Breaking Research: Clinical Research 1
Date/Time: Monday, Apr. 8, 2024 from 9:00 AM – 12:30 PM
Location: Poster Section 51